Literature DB >> 14976048

Phosphoinositide 3-kinase signaling is essential for ABL oncogene-mediated transformation of B-lineage cells.

Michael G Kharas1, Jonathan A Deane, Stephane Wong, Karen R O'Bosky, Naomi Rosenberg, Owen N Witte, David A Fruman.   

Abstract

BCR-ABL and v-ABL are oncogenic forms of the Abl tyrosine kinase that can cause leukemias in mice and humans. ABL oncogenes trigger multiple signaling pathways whose contribution to transformation varies among cell types. Activation of phosphoinositide 3-kinase (PI3K) is essential for ABL-dependent proliferation and survival in some cell types, and global PI3K inhibitors can enhance the antileukemia effects of the Abl kinase inhibitor imatinib. Although a significant fraction of BCR-ABL-induced human leukemias are of B-cell origin, little is known about PI3K signaling mechanisms in B-lineage cells transformed by ABL oncogenes. Here we show that activation of class I(A) PI3K and downstream inactivation of FOXO transcription factors are essential for survival of murine pro/pre-B cells transformed by v-ABL or BCR-ABL. In addition, analysis of mice lacking individual PI3K genes indicates that products of the Pik3r1 gene contribute to transformation efficiency by BCR-ABL. These findings establish a role for PI3K signaling in B-lineage transformation by ABL oncogenes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14976048     DOI: 10.1182/blood-2003-07-2193

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  36 in total

1.  A novel AMPK activator from Chinese herb medicine and ischemia phosphorylate the cardiac transcription factor FOXO3.

Authors:  Jingying Wang; Heng Ma; Xiaoyu Zhang; Leilei He; Jianming Wu; Xiaoping Gao; Jun Ren; Ji Li
Journal:  Int J Physiol Pathophysiol Pharmacol       Date:  2009-03-25

2.  Bcr-Abl activates the AKT/Fox O3 signalling pathway to restrict transforming growth factor-beta-mediated cytostatic signals.

Authors:  Azeddine Atfi; Lucile Abécassis; Marie-Francoise Bourgeade
Journal:  EMBO Rep       Date:  2005-10       Impact factor: 8.807

Review 3.  Mammalian target of rapamycin as a target in hematological malignancies.

Authors:  Kevin R Kelly; Julie H Rowe; Swaminathan Padmanabhan; Steffan T Nawrocki; Jennifer S Carew
Journal:  Target Oncol       Date:  2011-04-17       Impact factor: 4.493

4.  Inhibition of eIF4E cooperates with chemotherapy and immunotherapy in renal cell carcinoma.

Authors:  J Cao; X Sun; X Zhang; D Chen
Journal:  Clin Transl Oncol       Date:  2017-10-30       Impact factor: 3.405

5.  S6 kinase 2 potentiates interleukin-3-driven cell proliferation.

Authors:  Rebecca Cruz; Lee Hedden; Derek Boyer; Michael G Kharas; David A Fruman; Kay K Lee-Fruman
Journal:  J Leukoc Biol       Date:  2005-10-04       Impact factor: 4.962

6.  PI3K is involved in β1 integrin clustering by PSGL-1 and promotes β1 integrin-mediated Jurkat cell adhesion to fibronectin.

Authors:  Jixian Luo; Chunfeng Li; Tingshuang Xu; Wenai Liu; Xueqing Ba; Xiaoguang Wang; Xianlu Zeng
Journal:  Mol Cell Biochem       Date:  2014-01       Impact factor: 3.396

Review 7.  Metabolic effects of signal transduction inhibition in cancer assessed by magnetic resonance spectroscopy.

Authors:  Siver Andreas Moestue; Olav Engebraaten; Ingrid Susann Gribbestad
Journal:  Mol Oncol       Date:  2011-04-23       Impact factor: 6.603

Review 8.  Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies?

Authors:  Yanan Gao; Chase Y Yuan; Weiping Yuan
Journal:  Stem Cell Investig       Date:  2016-07-22

9.  Association between rs2981582 polymorphism in the FGFR2 gene and the risk of breast cancer in Mexican women.

Authors:  Efrén Murillo-Zamora; Hortensia Moreno-Macías; Elad Ziv; Isabelle Romieu; Eduardo Lazcano-Ponce; Angélica Angeles-Llerenas; Edelmiro Pérez-Rodríguez; Silvia Vidal-Millán; Laura Fejerman; Gabriela Torres-Mejía
Journal:  Arch Med Res       Date:  2013-09-18       Impact factor: 2.235

10.  Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells.

Authors:  Michael G Kharas; Matthew R Janes; Vanessa M Scarfone; Michael B Lilly; Zachary A Knight; Kevan M Shokat; David A Fruman
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.